KMDA Latest Press Releases

-- November 9, 2026 --

Kamada Reports Record-High First Nine Months 2026 Financial Results; Increases 2026 Annual Guidance and Projects Double-Digit Growth in Revenues and Profitability in 2027 Globe Newswire 7:02 AM

Kamada Declares Cash Dividend of $0.14 Per Share; The Company Continues its Record-High Year Globe Newswire 7:00 AM

-- November 2, 2026 --

Kamada to Announce Third Quarter and Nine Months Ended September 30, 2026, Financial Results on November 9, 2026 Globe Newswire 7:00 AM

-- October 19, 2026 --

Kamada Announces Participation in the Stifel 2026 Healthcare Conference and the Jefferies Global Healthcare Conference in London During November 2026 Globe Newswire 7:00 AM

-- October 6, 2026 --

Kamada Announces Expansion of Biosimilars Portfolio with the Launch of Two Additional Products in Israel Globe Newswire 7:00 AM

-- September 17, 2026 --

CDC Highlights Significant Increase in U.S. Rabies Exposures and Anti-Rabies Immunoglobulin Utilization; Kamada Confirms Sufficient KedRAB Supply to Meet Increased Demand Globe Newswire 7:00 AM

-- September 10, 2026 --

Kamada to Present at the H.C. Wainwright 28th Annual Global Investment Conference Globe Newswire 7:00 AM

-- September 3, 2026 --

Kamada Updates on Withholding Tax Procedures on Previously Announced Cash Dividend to Shareholders Globe Newswire 4:06 PM

-- August 17, 2026 --

Kamada Declares Cash Dividend of $0.17 Per Share; The Company Reported Record-High Revenue and Profitability for First Six Months of 2026 Globe Newswire 7:00 AM

-- August 12, 2026 --

Kamada Reports Record-High First Half and Second Quarter 2026 Financial Results, Representing Double-Digit Profitable Growth and the Strongest in Kamada's History; Affirms 2026 Annual Guidance Globe Newswire 7:05 AM

Kamada Announces Planned Transition of Chief Financial Officer Globe Newswire 7:00 AM

-- August 5, 2026 --

Kamada to Announce Second Quarter and First Half Ended June 30, 2026 Financial Results on August 12, 2026 Globe Newswire 7:00 AM

-- July 20, 2026 --

Kamada Announces a Three-Year $50 Million Sales Agreement to Supply Plasma to a Leading Biopharmaceutical Company focused on Plasma-derived Therapies Globe Newswire 7:00 AM

-- July 13, 2026 --

Kamada Highlights CYTOGAM Study Results Presented at the 2026 ISHLT Annual Meeting Globe Newswire 7:00 AM

Market Data Delayed 15 Minutes